Gensight Biologics SA (SIGHT) EUR0.025

Sell:€0.22Buy:€0.22€0.01 (2.63%)

Prices delayed by at least 15 minutes
Sell:€0.22
Buy:€0.22
Change:€0.01 (2.63%)
Deal now
Prices delayed by at least 15 minutes
Sell:€0.22
Buy:€0.22
Change:€0.01 (2.63%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Gensight Biologics SA is a France-based biopharmaceutical company. The Company develops and commercializes gene therapy-based treatments of retinal degenerative diseases. It develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The Company intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

Key people

Laurence Rodriguez
Chief Executive Officer, Director
Philippe Motte
Deputy Chief Executive Officer, Senior Vice President - Regulatory Affairs and Quality, Chief Pharmacist
Jan Eryk Umiastowski
Chief Financial Officer
Scott Jeffers
Chief Technology Officer
Magali Taiel
Chief Medical Officer
Michael S. Wyzga
Independent Chairman of the Board Director
Cedric Moreau
Director - Representative of Sofinnova Partners
Elsy Boglioli
Independent Director
Francoise de Craecker
Independent Director
Maritza C. Mcintyre
Independent Director
Click to see more

Key facts

  • EPIC
    SIGHT
  • Location
    France
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    FR0013183985
  • Market cap
    €29.76m
  • Employees
    12
  • Shares in issue
    124.77m
  • Exchange
    Euronext Paris
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.